Hydroxychloroquine in its current decades-old oral tablet form is subject to inconsistent dosing and side effects including nausea, vomiting, blurred vision, headache and overall toxicity.
Hydroxychloroquine has been heavily publicized as a promising drug treatment available today for Covid-19
On March 28th, the FDA approved the emergency use of HCQ for Covid-19 patients and health care workers in an unprecedented move.
This transformative delivery system will initially target Covid-19 through the FDA 505(b)(2) accelerated pathway provisions, and in the long term for the drug's FDA approved applications for malaria, lupus and rheumatoid arthritis - providing an innovation for those long-term patients who have depended on HCQ for decades and had to accept the side effects related to oral delivery.
While hydroxychloroquine is the subject of various early studies of its effectiveness against the Covid-19, its present on-label uses as a treatment against malaria, lupus and rheumatoid arthritis provides a ready market for this proposed new delivery system. This new delivery method should eliminate or reduce a number of the common side effects of this treatment, including nausea, vomiting, loss of appetite, diarrhea, dizziness, or headache by providing a controlled constant delivery.
Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time, potentially drastically reducing side effects from decades-old oral tablets. Safe, consistent doses will make the drug much more effective at reduced dosages required because the GI system is avoided with transdermal delivery.
CODEBASE VENTURES . "BKLLF" OTC stock ticker. "CODE" Canadian stock ticker is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 at this time.